Status:
RECRUITING
PET/MR for Characterization of Renal Masses (RMs)
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
Radiological Society of North America
Conditions:
Renal Tumor
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses tho...
Detailed Description
Renal cell carcinoma (RCC) is most commonly diagnosed as an incidental small renal mass (SRM, ≤4cm \[cT1a\]). The incidence of RCC has markedly increased in the last few decades due to the widespread ...
Eligibility Criteria
Inclusion
- Patients with known solid (\>25% total volume enhances) renal mass
- Renal mass size measuring \>2 to ≤7 cm
- Age \>18 years
- Ability to understand and the willingness to sign a written informed consent.
Exclusion
- Pregnancy
- Prior percutaneous biopsy of the renal mass
- Prior treatment of the renal mass
- Prior hemorrhage in the renal mass
- Contraindication to MRI or PET
- Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat \[classic angiomyolipoma\] or enhancing less than 25% of its volume \[considered a cystic renal mass\])
- Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.);
- More than 3 renal masses at time of initial diagnosis
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT06076538
Start Date
August 1 2023
End Date
June 1 2028
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390